pulmonary fibrosis/diarré

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 63 resultat

Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Nintedanib is an important drug for the treatment of idiopathic pulmonary fibrosis (IPF). However, the drug is discontinued in some patients who present with diarrhea. In this study, we aimed to assess the drug continuation rate in patients who developed diarrhea during nintedanib

Collagenous colitis and pulmonary fibrosis. Manifestations of a single disease?

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A 66-year-old man developed chronic watery diarrhea and progressive dyspnea over 1-year. Colonic biopsy revealed a thickened subepithelial collagen layer consistent with collagenous colitis; open lung biopsy revealed pulmonary fibrosis. Only one previous report links extraintestinal manifestations

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung function decline. OBJECTIVE To evaluate the results of a large cohort of IPF patients treated with nintedanib within a compassionate use

Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and peripheral neuropathy, and these are moderate and manageable.

Eosinophilic gastroenteritis with malabsorption, extensive villous atrophy, recurrent hemorrhage and chronic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A patient with diffuse eosinophilic gastroenteritis, associated with progressive chronic interstitial pulmonary fibrosis, was followed for 29 years. His major symptoms were recurrent gastrointestinal bleeding, anemia, diarrhea, malabsorption, and increasing respiratory insufficiency. Multiple

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Current clinical practice guidelines for idiopathic pulmonary fibrosis (IPF) conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment sequence has not been established, and the data of treatment sequence from pirfenidone to nintedanib are limited. This

Secretory diarrhea with islet cell hyperplasia and increased immunohistochemical reactivity to serotonin.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Two patients with secretory diarrhea and signs and symptoms consistent with the Verner-Morrison syndrome and islet cell hyperplasia are described. Both patients responded well to subtotal pancreatectomies. The morphologic changes in the pancreata were characterized by proliferation of islets

Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Idiopathic pulmonary fibrosis (IPF) is a progressive and deadly disease. The US Food and Drug Administration recently approved two medications for the treatment of IPF - pirfenidone and nintedanib. Given the limited clinical experience with these agents, a number of questions remain

The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease that primarily affects older individuals. Nintedanib, a tyrosine kinase inhibitor, has been approved for the treatment of IPF in several countries. The safety and tolerability of nintedanib have been

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung function. METHODS Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS(®) trials, we characterized the safety and tolerability of nintedanib 150 mg

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Nintedanib represents an antifibrotic compound able to slow down disease progression of patients with idiopathic pulmonary fibrosis (IPF). To investigate the safety and efficacy of nintedanib in patients with IPF in a real-life setting. This was a multicentre, retrospective, observational, real-life

Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. METHODS We performed a

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Introduction: The safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) have been characterized using data from clinical trials. Methods:

Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Background: We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Objectives:

Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

In idiopathic pulmonary fibrosis (IPF), several factors may have a negative impact on the nutritional status, including an increased respiratory muscles load, release of inflammation mediators, the coexistence of hypoxemia, and physical inactivity. Nutritional abnormalities also have an impact on

Tidigare
1
2
3
4
5
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning